Risk of Reactivation of Hepatitis B Virus (HBV) and Tuberculosis (TB) and Complications of Hepatitis C Virus (HCV) Following Tocilizumab Therapy: A Systematic Review to Inform Risk Assessment in the COVID-19 Era
Open Access
- 20 August 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 8, 706482
Abstract
Objectives:Tocilizumab (TCZ), an IL-6 receptor antagonist, is used in the treatment of severe COVID-19 caused by infection with SARS-CoV-2. However, unintended consequences of TCZ therapy include reactivation of tuberculosis (TB) or hepatitis B virus (HBV), and worsening of hepatitis C virus (HCV). We set out to assimilate existing data for these complications, in order to help inform evidence-based risk assessments for the use of TCZ, and thus to reduce the risk of serious but preventable complications.Methods:We searched the global WHO database of Individual Case Safety Reports (ICSRs) and adverse drug reactions (ADRs) (“VigiBase”) and undertook a systematic literature review, in accordance with PRISMA guidelines. We generated mean cumulative incidence estimates for infection complications.Results:Mean cumulative incidence of HBV and TB were 3.3 and 4.3%, respectively, in patients receiving TCZ. Insufficient data were available to generate estimates for HCV. These estimates derive from heterogeneous studies pre-dating SARS-CoV-2, with differing epidemiology and varied approaches to screening and prophylaxis, so formal meta-analysis was not possible.Conclusions:We underline the need for careful individual risk assessment prior to TCZ prescription, and present an algorithm to guide clinical stratification. There is an urgent need for ongoing collation of safety data as TCZ therapy is used in COVID.Keywords
All Related Versions
Funding Information
- Wellcome
- GlaxoSmithKline
This publication has 60 references indexed in Scilit:
- Systemic diseases and biotherapies: Understanding, evaluating, and preventing the risk of hepatitis B reactivationJoint Bone Spine, 2014
- IL-6 Controls the Innate Immune Response against Listeria monocytogenes via Classical IL-6 SignalingThe Journal of Immunology, 2013
- Integrated safety in tocilizumab clinical trialsArthritis Research & Therapy, 2011
- IL-6 Mediates the Susceptibility of Glycoprotein 130 Hypermorphs to Toxoplasma gondiiThe Journal of Immunology, 2011
- Anti-IL-6 Receptor Antibody Causes Less Promotion of Tuberculosis Infection than Anti-TNF- Antibody in MiceJournal of Immunology Research, 2011
- Not interferon, but interleukin‐6 controls early gene expression in hepatitis B virus infection†‡Hepatology, 2009
- Lack of IL-6 during Coxsackievirus Infection Heightens the Early Immune Response Resulting in Increased Severity of Chronic Autoimmune MyocarditisPLOS ONE, 2009
- Interleukin-6 haplotypes and the response to therapy of chronic hepatitis C virus infectionGenes & Immunity, 2009
- HBV replication is significantly reduced by IL-6Journal of Biomedical Science, 2009
- Effect of IL-6 Deficiency on Susceptibility to HSV-1 Respiratory Infection and Intrinsic Macrophage Antiviral ResistanceJournal of Interferon & Cytokine Research, 2008